ARD 101
Alternative Names: ARD-101; Denatonium acetate monohydrateLatest Information Update: 13 Nov 2025
At a glance
- Originator Aardvark Therapeutics
- Class Anti-inflammatories; Obesity therapies; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Yes - Prader-Willi syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Prader-Willi syndrome
- Phase I Obesity
- Discontinued Weight gain
Most Recent Events
- 04 Nov 2025 Efficacy and adverse event data from phase II trial in Obesity released by Aardvark Therapeutics
- 01 Jul 2025 Phase-III clinical trials in Prader-Willi syndrome (In children, In adolescents, In adults, In the elderly) in Australia (PO) (NCT07197034)
- 14 May 2025 Phase-I clinical trials in Obesity (PO) (Aardvark Therapeutics pipeline; May 2025)